Home
Clinical Trials
Global Anticoagulant Registry...

Global Anticoagulant Registry in the Field

Last Updated: 2021-04-28

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

57250 participants

Study Classification

OBSERVATIONAL

Study Start Date

2009-12-21

Study Completion Date

2020-05-18

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The Global Anticoagulant Registry in the FIELD-Atrial Fibrillation (GARFIELD-AF Registry) is a non-interventional, observational study that characterized a global population of non-valvular atrial fibrillation patients. The registry was used to document global baseline characteristics, current treatment strategies and outcome measures. Characterisation of a number of AF sub-populations was also completed. GARFIELD-AF is an independent academic research initiative sponsored by the Thrombosis Research Institute (London, UK) and supported by an unrestricted research grant from Bayer AG (Berlin, Germany).

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Study in Atrial Fibrillation (AF) Patients at High Risk of Stroke

NCT05421533

Atrial Fibrillation

TERMINATED

GLORIA-AF Registry Program (Phase II/III - EU/EEA Member States)

NCT01671007

Stroke Atrial Fibrillation

COMPLETED

Clinical Performance of the Globe® Mapping and Ablation System for the Treatment of Atrial Fibrillation

NCT04954911

Atrial Fibrillation

COMPLETED

Affera Global Registry

NCT06026345

Atrial Fibrillation

RECRUITING

GLORIA-AF Registry Program (Phase I)

NCT01428765

Atrial Fibrillation

COMPLETED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Using data from more than 1000 randomly selected centres across 35 countries, representing all possible care settings, the registry will help to characterize real-life anticoagulant treatment patterns and outcomes, including rates of stroke and bleeding complications, as well as provide data on other important issues, such as physicians' compliance with guidelines and patients' adherence to therapy. This is particularly timely as standard practice moves away from vitamin K antagonist (VKA)-dominated therapy and towards a new era of novel oral anticoagulants (OACs), i.e. direct Factor Xa inhibitors and direct thrombin inhibitors.

To ensure a dataset that truly reflects current practice, the investigators are requested to prospectively enrol all newly diagnosed patients with non-valvular AF who have at least one additional investigator-determined risk factor for stroke. Patients are consecutively recruited into one of five cohorts and followed up for at least 2 years.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Atrial Fibrillation

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Cohort 1

Cohort complete with 5,088 retrospective patients and 5,499 prospective patients recruited from 19 countries.